Genprex, Inc. (GNPX) 10-Year Financial Performance & Capital Metrics

GNPX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutGenprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.Show more

Revenue $0
EBITDA -$21M +31.9%
Net Income -$21M +31.6%
EPS (Diluted) -266.95 +76.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -467.24% -124.8%
ROIC -4555.22% -95.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.02%

ROCE

10Y Avg-236.48%

5Y Avg-183.21%

3Y Avg-250.99%

Latest-468.63%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-5.88K	-13.07K	-22.78K	-22.53K	-25.57K	-15K	-6.69K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-1.22%	-0.74%	0.01%	-0.13%	0.41%	0.55%
Operating Expenses+	1.07M	4.13M	3.31M	12.36M	10.67M	17.94M	20.65M	23.81M	31.06M	21.17M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	865.7K	3.78M	3.02M	11.39M	8.7M	10.64M	11.68M	12.3M	13.44M	10.63M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	201.96K	354.88K	289.93K	971.43K	1.97M	7.3M	8.97M	11.51M	17.62M	10.54M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	3.24K	5.88K	0	0	0	0	0	0
Operating Income+	-1.07M	-4.13M	-3.31M	-12.36M	-10.68M	-17.96M	-20.67M	-23.83M	-31.08M	-21.17M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.86%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
EBITDA+	-1.07M	-4.13M	-3.31M	-12.36M	-10.67M	-17.94M	-20.65M	-23.81M	-31.06M	-21.17M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.87%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
D&A (Non-Cash Add-back)	2.06K	862	3.24K	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
EBIT	-1.07M	-4.13M	-3.31M	-12.33M	-10.65M	-17.94M	-20.66M	-23.74M	-31.08M	-21.11M
Net Interest Income+	0	0	-1.81K	-8.8K	27.91K	18.81K	5.13K	90.1K	215.11K	63.57K
Interest Income	0	0	80	29.18K	27.91K	18.81K	5.13K	90.1K	215.11K	63.57K
Interest Expense	0	0	1.89K	37.98K	0	0	0	0	0	0
Other Income/Expense	0	0	-1.81K	-8.8K	27.91K	18.81K	5.13K	90.1K	215.11K	63K
Pretax Income+	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	80	29.18K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-2.86%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
Net Income (Continuing)	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1146.50	-763.00	-576.50	-1797.00	-1329.50	-1009.00	-877.50	-990.00	-1128.00	-266.95
EPS Growth %	-	0.33%	0.24%	-2.12%	0.26%	0.24%	0.13%	-0.13%	-0.14%	0.76%
EPS (Basic)	-1162.50	-765.00	-577.50	-1798.50	-1332.00	-1009.00	-877.50	-990.00	-1129.00	-266.95
Diluted Shares Outstanding	933	5.42K	5.75K	6.89K	8.01K	17.76K	23.55K	23.98K	27.36K	80.12K
Basic Shares Outstanding	920	5.4K	5.74K	6.88K	8K	17.76K	23.54K	23.96K	27.34K	80.12K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	250.05K	1.64M	193.57K	8.85M	2.98M	30.72M	39.14M	21.47M	7.53M	2.08M
Cash & Short-Term Investments	234.22K	1.6M	161.25K	8.6M	2M	27.32M	38.63M	20.95M	6.74M	1.6M
Cash Only	234.22K	1.6M	161.25K	8.6M	2M	27.32M	38.63M	20.95M	6.74M	1.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	9.3K	655	127	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	801.78K	3.01M	0	0	0	0
Days Inventory Outstanding	-	-	-	-	22.39K	48.25K	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	34.85K	794.14K	475.81K
Total Non-Current Assets+	160.04K	271.7K	1.07M	421.89K	557.59K	651.81K	3.72M	3.61M	3.14M	2.05M
Property, Plant & Equipment	1.04K	5.16K	7.8K	24.35K	44.65K	39.44K	48.61K	23.03K	7.86K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	156.48K	241.04K	298.57K	379.45K	491.2K	601.63K	642.36K	702.1K	773.48K	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.52K	25.51K	759.59K	18.09K	21.73K	10.74K	3.03M	2.89M	2.36M	2.05M
Total Assets+	410.09K	1.91M	1.26M	9.27M	3.53M	31.37M	42.86M	25.09M	10.67M	4.12M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	3.66%	-0.34%	6.36%	-0.62%	7.88%	0.37%	-0.41%	-0.57%	-0.61%
Total Current Liabilities+	16.35K	285.66K	830.96K	387.82K	510.68K	450.72K	1.59M	2.81M	3.25M	2.5M
Accounts Payable	16.35K	109.66K	629.07K	295.07K	436.26K	192.97K	973.2K	442.93K	1.4M	1.07M
Days Payables Outstanding	-	-	-	18.3K	12.18K	3.09K	15.76K	6.32K	34K	58.59K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	36K	201.89K	92.75K	74.43K	257.76K	612.1K	2.37M	1.86M	1.43M
Current Ratio	15.29x	5.74x	0.23x	22.81x	5.83x	68.15x	24.69x	7.64x	2.31x	0.83x
Quick Ratio	15.29x	5.74x	0.23x	22.81x	4.26x	61.47x	24.69x	7.64x	2.31x	0.83x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	16.35K	285.66K	830.96K	387.82K	510.68K	450.72K	1.59M	2.81M	3.25M	2.5M
Total Debt+	0	0	201.89K	92.75K	0	0	0	0	0	0
Net Debt	-234.22K	-1.6M	40.64K	-8.51M	-2M	-27.32M	-38.63M	-20.95M	-6.74M	-1.6M
Debt / Equity	-	-	0.47x	0.01x	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-1752.56x	-325.51x	-	-	-	-	-	-
Total Equity+	393.74K	1.62M	428.57K	8.88M	3.02M	30.92M	41.28M	22.27M	7.42M	1.62M
Equity Growth %	-	3.13%	-0.74%	19.72%	-0.66%	9.23%	0.34%	-0.46%	-0.67%	-0.78%
Book Value per Share	422.01	299.96	74.53	1289.74	377.28	1740.70	1752.81	929.00	271.12	20.22
Total Shareholders' Equity	393.74K	1.62M	428.57K	8.88M	3.02M	30.92M	41.28M	22.27M	7.42M	1.62M
Common Stock	308	328	11.72K	15.24K	19.26K	43.12K	47.87K	1.2K	1.49K	10.86K
Retained Earnings	-10.01M	-14.14M	-17.45M	-29.82M	-40.48M	-58.42M	-79.09M	-102.83M	-133.69M	-154.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-688.26K	-1.25M	-2.17M	-6.85M	-6.92M	-13.94M	-14.28M	-17.78M	-24.74M	-17.15M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.81%	-0.74%	-2.15%	-0.01%	-1.01%	-0.03%	-0.24%	-0.39%	0.31%
Net Income	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-19.59M	-23.74M	-30.86M	-21.11M
Depreciation & Amortization	2.06K	862	3.24K	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
Stock-Based Compensation	441.38K	2.66M	1.32M	5.44M	3.53M	4.25M	5.35M	0	5.41M	3.3M
Deferred Taxes	0	0	0	0	-3.41M	-4.54M	-4.61M	0	0	0
Other Non-Cash Items	-59	269	545	5.45M	3.41M	4.54M	3.54M	4.73M	0	773.48K
Working Capital Changes	-61.98K	225.62K	-184.57K	84.54K	192.99K	-261.28K	1.01M	1.2M	698.13K	-121.08K
Change in Receivables	0	-1	-663	-453	8.64K	528	127	-34.85K	34.85K	0
Change in Inventory	0	0	0	-231.46K	46.81K	0	0	0	0	0
Change in Payables	0	0	0	-443.14K	141.19K	-247.29K	780.23K	-530.27K	954.69K	-323.31K
Cash from Investing+	-21.28K	-89.53K	-63.42K	-103.32K	-946.9K	-2.34M	-83.8K	97.73K	-71.21K	1.17K
Capital Expenditures	-21.28K	-89.53K	-63.42K	-103.32K	-946.9K	-2.34M	-83.8K	-59.73K	-71.38K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-20	-85	-58	-81	0	0	0	157.47K	169	1.17K
Cash from Financing+	724.91K	2.71M	793.97K	15.39M	1.27M	41.59M	25.68M	6.43K	10.59M	12.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-277.12M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	724.91K	-2.71M	0	0	0	0	0	0	0	277.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-709.54K	-1.34M	-2.24M	-6.95M	-7.87M	-16.27M	-14.37M	-17.78M	-24.81M	-17.15M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.89%	-0.67%	-2.11%	-0.13%	-1.07%	0.12%	-0.24%	-0.4%	0.31%
FCF per Share	-760.50	-246.96	-388.70	-1009.27	-981.48	-916.18	-610.16	-741.50	-906.96	-214.05
FCF Conversion (FCF/Net Income)	0.64x	0.30x	0.66x	0.55x	0.65x	0.78x	0.69x	0.75x	0.80x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-271.68%	-409.41%	-322.79%	-265.79%	-179%	-105.73%	-57.25%	-74.71%	-207.88%	-467.24%
Return on Invested Capital (ROIC)	-	-3403.94%	-1010.3%	-2202.06%	-1149.48%	-583.44%	-496.49%	-900.68%	-2331.34%	-4555.22%
Debt / Equity	-	-	0.47x	0.01x	-	-	-	-	-	-
Interest Coverage	-	-	-1752.56x	-325.51x	-	-	-	-	-	-
FCF Conversion	0.64x	0.30x	0.66x	0.55x	0.65x	0.78x	0.69x	0.75x	0.80x	0.81x

Frequently Asked Questions

Growth & Financials

Genprex, Inc. (GNPX) grew revenue by 0.0% over the past year. Growth has been modest.

Genprex, Inc. (GNPX) reported a net loss of $16.8M for fiscal year 2024.

Dividend & Returns

Yes, Genprex, Inc. (GNPX) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Genprex, Inc. (GNPX) has a return on equity (ROE) of -467.2%. Negative ROE indicates the company is unprofitable.

Genprex, Inc. (GNPX) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Genprex, Inc. (GNPX) 10-Year Financial Performance & Capital Metrics

GNPX • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

Revenue $0
EBITDA -$21M +31.9%
Net Income -$21M +31.6%
EPS (Diluted) -266.95 +76.3%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -467.24% -124.8%
ROIC -4555.22% -95.4%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.2x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 3 (bottom 3%)
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.16%

EPS CAGR

10Y-

5Y-

3Y-

TTM92.02%

ROCE

10Y Avg-236.48%

5Y Avg-183.21%

3Y Avg-250.99%

Latest-468.63%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	0	0	0	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	0	0	0	-5.88K	-13.07K	-22.78K	-22.53K	-25.57K	-15K	-6.69K
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-	-	-	-	-1.22%	-0.74%	0.01%	-0.13%	0.41%	0.55%
Operating Expenses+	1.07M	4.13M	3.31M	12.36M	10.67M	17.94M	20.65M	23.81M	31.06M	21.17M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	865.7K	3.78M	3.02M	11.39M	8.7M	10.64M	11.68M	12.3M	13.44M	10.63M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	201.96K	354.88K	289.93K	971.43K	1.97M	7.3M	8.97M	11.51M	17.62M	10.54M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	3.24K	5.88K	0	0	0	0	0	0
Operating Income+	-1.07M	-4.13M	-3.31M	-12.36M	-10.68M	-17.96M	-20.67M	-23.83M	-31.08M	-21.17M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-	-2.86%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
EBITDA+	-1.07M	-4.13M	-3.31M	-12.36M	-10.67M	-17.94M	-20.65M	-23.81M	-31.06M	-21.17M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-	-2.87%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
D&A (Non-Cash Add-back)	2.06K	862	3.24K	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
EBIT	-1.07M	-4.13M	-3.31M	-12.33M	-10.65M	-17.94M	-20.66M	-23.74M	-31.08M	-21.11M
Net Interest Income+	0	0	-1.81K	-8.8K	27.91K	18.81K	5.13K	90.1K	215.11K	63.57K
Interest Income	0	0	80	29.18K	27.91K	18.81K	5.13K	90.1K	215.11K	63.57K
Interest Expense	0	0	1.89K	37.98K	0	0	0	0	0	0
Other Income/Expense	0	0	-1.81K	-8.8K	27.91K	18.81K	5.13K	90.1K	215.11K	63K
Pretax Income+	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	80	29.18K	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-	-2.86%	0.2%	-2.73%	0.14%	-0.68%	-0.15%	-0.15%	-0.3%	0.32%
Net Income (Continuing)	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-20.66M	-23.74M	-30.86M	-21.11M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1146.50	-763.00	-576.50	-1797.00	-1329.50	-1009.00	-877.50	-990.00	-1128.00	-266.95
EPS Growth %	-	0.33%	0.24%	-2.12%	0.26%	0.24%	0.13%	-0.13%	-0.14%	0.76%
EPS (Basic)	-1162.50	-765.00	-577.50	-1798.50	-1332.00	-1009.00	-877.50	-990.00	-1129.00	-266.95
Diluted Shares Outstanding	933	5.42K	5.75K	6.89K	8.01K	17.76K	23.55K	23.98K	27.36K	80.12K
Basic Shares Outstanding	920	5.4K	5.74K	6.88K	8K	17.76K	23.54K	23.96K	27.34K	80.12K
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	250.05K	1.64M	193.57K	8.85M	2.98M	30.72M	39.14M	21.47M	7.53M	2.08M
Cash & Short-Term Investments	234.22K	1.6M	161.25K	8.6M	2M	27.32M	38.63M	20.95M	6.74M	1.6M
Cash Only	234.22K	1.6M	161.25K	8.6M	2M	27.32M	38.63M	20.95M	6.74M	1.6M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	9.3K	655	127	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	801.78K	3.01M	0	0	0	0
Days Inventory Outstanding	-	-	-	-	22.39K	48.25K	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	34.85K	794.14K	475.81K
Total Non-Current Assets+	160.04K	271.7K	1.07M	421.89K	557.59K	651.81K	3.72M	3.61M	3.14M	2.05M
Property, Plant & Equipment	1.04K	5.16K	7.8K	24.35K	44.65K	39.44K	48.61K	23.03K	7.86K	0
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	156.48K	241.04K	298.57K	379.45K	491.2K	601.63K	642.36K	702.1K	773.48K	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	2.52K	25.51K	759.59K	18.09K	21.73K	10.74K	3.03M	2.89M	2.36M	2.05M
Total Assets+	410.09K	1.91M	1.26M	9.27M	3.53M	31.37M	42.86M	25.09M	10.67M	4.12M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-	3.66%	-0.34%	6.36%	-0.62%	7.88%	0.37%	-0.41%	-0.57%	-0.61%
Total Current Liabilities+	16.35K	285.66K	830.96K	387.82K	510.68K	450.72K	1.59M	2.81M	3.25M	2.5M
Accounts Payable	16.35K	109.66K	629.07K	295.07K	436.26K	192.97K	973.2K	442.93K	1.4M	1.07M
Days Payables Outstanding	-	-	-	18.3K	12.18K	3.09K	15.76K	6.32K	34K	58.59K
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	0	36K	201.89K	92.75K	74.43K	257.76K	612.1K	2.37M	1.86M	1.43M
Current Ratio	15.29x	5.74x	0.23x	22.81x	5.83x	68.15x	24.69x	7.64x	2.31x	0.83x
Quick Ratio	15.29x	5.74x	0.23x	22.81x	4.26x	61.47x	24.69x	7.64x	2.31x	0.83x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	0	0	0	0	0	0	0	0	0	0
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	16.35K	285.66K	830.96K	387.82K	510.68K	450.72K	1.59M	2.81M	3.25M	2.5M
Total Debt+	0	0	201.89K	92.75K	0	0	0	0	0	0
Net Debt	-234.22K	-1.6M	40.64K	-8.51M	-2M	-27.32M	-38.63M	-20.95M	-6.74M	-1.6M
Debt / Equity	-	-	0.47x	0.01x	-	-	-	-	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-1752.56x	-325.51x	-	-	-	-	-	-
Total Equity+	393.74K	1.62M	428.57K	8.88M	3.02M	30.92M	41.28M	22.27M	7.42M	1.62M
Equity Growth %	-	3.13%	-0.74%	19.72%	-0.66%	9.23%	0.34%	-0.46%	-0.67%	-0.78%
Book Value per Share	422.01	299.96	74.53	1289.74	377.28	1740.70	1752.81	929.00	271.12	20.22
Total Shareholders' Equity	393.74K	1.62M	428.57K	8.88M	3.02M	30.92M	41.28M	22.27M	7.42M	1.62M
Common Stock	308	328	11.72K	15.24K	19.26K	43.12K	47.87K	1.2K	1.49K	10.86K
Retained Earnings	-10.01M	-14.14M	-17.45M	-29.82M	-40.48M	-58.42M	-79.09M	-102.83M	-133.69M	-154.8M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-688.26K	-1.25M	-2.17M	-6.85M	-6.92M	-13.94M	-14.28M	-17.78M	-24.74M	-17.15M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-	-0.81%	-0.74%	-2.15%	-0.01%	-1.01%	-0.03%	-0.24%	-0.39%	0.31%
Net Income	-1.07M	-4.13M	-3.31M	-12.37M	-10.65M	-17.94M	-19.59M	-23.74M	-30.86M	-21.11M
Depreciation & Amortization	2.06K	862	3.24K	5.88K	13.07K	22.78K	22.53K	25.57K	15K	6.69K
Stock-Based Compensation	441.38K	2.66M	1.32M	5.44M	3.53M	4.25M	5.35M	0	5.41M	3.3M
Deferred Taxes	0	0	0	0	-3.41M	-4.54M	-4.61M	0	0	0
Other Non-Cash Items	-59	269	545	5.45M	3.41M	4.54M	3.54M	4.73M	0	773.48K
Working Capital Changes	-61.98K	225.62K	-184.57K	84.54K	192.99K	-261.28K	1.01M	1.2M	698.13K	-121.08K
Change in Receivables	0	-1	-663	-453	8.64K	528	127	-34.85K	34.85K	0
Change in Inventory	0	0	0	-231.46K	46.81K	0	0	0	0	0
Change in Payables	0	0	0	-443.14K	141.19K	-247.29K	780.23K	-530.27K	954.69K	-323.31K
Cash from Investing+	-21.28K	-89.53K	-63.42K	-103.32K	-946.9K	-2.34M	-83.8K	97.73K	-71.21K	1.17K
Capital Expenditures	-21.28K	-89.53K	-63.42K	-103.32K	-946.9K	-2.34M	-83.8K	-59.73K	-71.38K	0
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-20	-85	-58	-81	0	0	0	157.47K	169	1.17K
Cash from Financing+	724.91K	2.71M	793.97K	15.39M	1.27M	41.59M	25.68M	6.43K	10.59M	12.01M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	-277.12M
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	724.91K	-2.71M	0	0	0	0	0	0	0	277.12M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-709.54K	-1.34M	-2.24M	-6.95M	-7.87M	-16.27M	-14.37M	-17.78M	-24.81M	-17.15M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	-	-0.89%	-0.67%	-2.11%	-0.13%	-1.07%	0.12%	-0.24%	-0.4%	0.31%
FCF per Share	-760.50	-246.96	-388.70	-1009.27	-981.48	-916.18	-610.16	-741.50	-906.96	-214.05
FCF Conversion (FCF/Net Income)	0.64x	0.30x	0.66x	0.55x	0.65x	0.78x	0.69x	0.75x	0.80x	0.81x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-271.68%	-409.41%	-322.79%	-265.79%	-179%	-105.73%	-57.25%	-74.71%	-207.88%	-467.24%
Return on Invested Capital (ROIC)	-	-3403.94%	-1010.3%	-2202.06%	-1149.48%	-583.44%	-496.49%	-900.68%	-2331.34%	-4555.22%
Debt / Equity	-	-	0.47x	0.01x	-	-	-	-	-	-
Interest Coverage	-	-	-1752.56x	-325.51x	-	-	-	-	-	-
FCF Conversion	0.64x	0.30x	0.66x	0.55x	0.65x	0.78x	0.69x	0.75x	0.80x	0.81x

Frequently Asked Questions

Growth & Financials

Genprex, Inc. (GNPX) grew revenue by 0.0% over the past year. Growth has been modest.

Genprex, Inc. (GNPX) reported a net loss of $16.8M for fiscal year 2024.

Dividend & Returns

Yes, Genprex, Inc. (GNPX) pays a dividend with a yield of 100.00%. This makes it attractive for income-focused investors.

Genprex, Inc. (GNPX) has a return on equity (ROE) of -467.2%. Negative ROE indicates the company is unprofitable.

Genprex, Inc. (GNPX) had negative free cash flow of $15.1M in fiscal year 2024, likely due to heavy capital investments.